Radiation therapy market worth $6.8 billion by 2023

By News Release

 

The global radiotherapy market is projected to reach $6.8 billion by 2023, up from $5.6 billion in 2018, at a compound annual growth rate (CAGR) of 4.1%, according to the new market research report, "Radiotherapy Market by Type (External (IGRT, IMRT, 3D-CRT, Stereotactic), Brachytherapy (LDR, HDR)), Product (LINAC, CyberKnife, Gamma Knife, Tomotherapy, Particle Therapy, Cyclotron), Application (Prostate, Breast), End User (Hospital) - Forecasts to 2023." The report is published by MarketsandMarkets.

Technological advancements in radiotherapy and the rising incidence of cancer are the major factors driving the growth of this market. Additionally, the growing adoption of radiotherapy procedures for cancer treatment, increasing use of particle therapy for cancer treatment, and the rising number of conferences and symposia focusing on the advancements in radiotherapy are some of the other major drivers of this market.

The prostate cancer segment is expected to account for the second-largest share of the external beam radiotherapy market, by application, in 2018 

Based on application, the external beam radiotherapy market is segmented into prostate cancer, breast cancer, lung cancer, head & neck cancer, colorectal cancer, and other cancers. The prostate cancer segment is expected to account for the second-largest share of the radiotherapy market in 2018. The growing incidence of prostate cancer and the high success rates and minimal long-term risks achieved with external beam radiotherapy are the major factors driving the growth of this market segment.

Particle beam therapy to register the highest CAGR in the external beam radiotherapy market during the forecast period 

Based on type, the external beam radiotherapy market is classified into IGRT, IMRT, stereotactic therapy, particle beam therapy, and 3D-CRT. The IMRT segment is further classified into VMAT and TomoTherapy. The particle beam therapy segment is expected to witness the highest CAGR during the forecast period. Advancements in the field of particle beam therapy (such as PBS) and increasing research activities in the field of radiation oncology using proton therapy systems are the key factors driving the growth of this segment.

North America to dominate the radiotherapy market during the forecast period 

The radiotherapy market is segmented into four regional segments, namely, North AmericaEuropeAsia Pacific, and the Rest of the World. The North American region is expected to account for the largest share of the Radiotherapy Market in 2018. The rising incidence of cancer, easy accessibility and high adoption of advanced diagnostic technologies (owing to the significant per capita annual healthcare expenditure in the US and Canada), and favorable government initiatives that are creating awareness and promoting the adoption of radiotherapy among key end users are some of the major factors driving the growth of the Radiotherapy Market in North America.

Major Players

The major players operating in the radiotherapy market are Varian Medical Systems, Inc. (US), Elekta (Sweden), Accuray Incorporated (US), Ion Beam Applications SA (Belgium), ViewRay, Inc. (US), IsoRay Medical, Inc. (US), Hitachi Ltd. (Japan), Panacea Medical Technologies Pvt. Ltd. (India), Provision Healthcare (US), Mevion Medical Systems, Inc. (US), Sumitomo Heavy Industries, Ltd. (Japan), Optivus Proton Therapy, Inc. (US), P-cure Ltd. (Israel), Theragenics Corporation (US), and C.R.Bard, Inc. (US).

 

Back To Top

Radiation therapy market worth $6.8 billion by 2023 .  Appl Rad Oncol. 

By News Release| January 11, 2019
Categories:  Section

About the Author

News Release

News Release

 



Copyright © Anderson Publishing, Ltd

 2019
    Agility CMS